{"id":37754,"date":"2018-09-27T12:02:35","date_gmt":"2018-09-27T16:02:35","guid":{"rendered":"https:\/\/decisionresourcesgroup.com\/?p=37754"},"modified":"2024-07-05T16:45:15","modified_gmt":"2024-07-05T16:45:15","slug":"common-office-dispensing-oral-prostate-cancer-drugs","status":"publish","type":"post","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/blog\/common-office-dispensing-oral-prostate-cancer-drugs\/","title":{"rendered":"How Common is In-Office Dispensing of Oral Prostate Cancer Drugs?"},"content":{"rendered":"

\"\"<\/p>\n

The growing trend of physicians dispensing of oral oncolytics directly to patients disrupts the U.S. reimbursement system\u2019s traditional reliance upon insurers\u2019 specialty pharmacies.<\/p>\n

Key finding: <\/strong>\u00a0Three quarters of oncologists and urologists surveyed by DRG reported that their practices have the capability to dispense oral prostate cancer drugs through their practice\u2019s licensed pharmacy (most common) or from an in-house supply. This trend, often called in-office dispensing (IOD), enables patients to get their oral drugs directly from their physician\u2019s office or on-site pharmacies, instead of using their insurers\u2019 specialty pharmacies. The practice can save time for the patient but also provides an extra revenue stream for the practice.<\/p>\n

 <\/p>\n

The \u201cso what\u201d for decision makers:<\/strong> Oncologists have historically administered IV cancer drugs to their patients and sought reimbursement from insurers. Increasingly, as more oral therapies come to market, they are increasingly dispensing oral products, such as Xtandi and Zytiga, from provider-owned pharmacies or in-office stock. Although some managed care organizations are concerned the practice diverts valuable scripts away from their specialty pharmacies, many do accommodate the practice. This report will help drug developers with oral products understand the dynamic reimbursement and purchasing system resulting from IOD and impact on prostate cancer therapies.<\/p>\n

 <\/p>\n

Learn more about the related DRG report:<\/strong><\/p>\n

Prostate Cancer | Access & Reimbursement| US | Physician Dispensing of Oral Oncolytics in Prostate Cancer<\/a><\/p>\n

 <\/p>\n

Key questions answered in the full report:<\/strong><\/p>\n